Assessment of C2-domain sCD33 levels in healthy and AML patient samples
| Variable . | Sample . | Concentration, nM . | Concentration, ng/mL . |
|---|---|---|---|
| NHS | Individual 1 | 0.23 | 6.15 |
| Individual 2 | NR | NR | |
| Individual 3 | NR | NR | |
| Individual 4 | 0.21 | 5.59 | |
| Individual 5 | NR | NR | |
| Individual 6 | 0.25 | 6.73 | |
| Individual 7 | 0.24 | 6.39 | |
| Individual 8 | NR | NR | |
| Individual 9 | 0.23 | 6.14 | |
| Individual 10 | 0.21 | 5.69 | |
| Mean NHS (reportable) | 0.23 | 6.12 | |
| AML donor serum (AML) | AML Donor 1 | 0.14 | 3.76 |
| AML Donor 2 | 0.14 | 3.71 | |
| AML Donor 3 | NR | NR | |
| AML Donor 4 | 0.15 | 3.92 | |
| AML Donor 5 | 0.16 | 4.32 | |
| AML Donor 6 | 0.13 | 3.61 | |
| AML Donor 7 | NR | NR | |
| AML Donor 8 | 0.17 | 4.44 | |
| AML Donor 9 | 0.14 | 3.81 | |
| AML Donor 10 | NR | NR | |
| Mean AML (reportable) | 0.15 | 3.94 |
| Variable . | Sample . | Concentration, nM . | Concentration, ng/mL . |
|---|---|---|---|
| NHS | Individual 1 | 0.23 | 6.15 |
| Individual 2 | NR | NR | |
| Individual 3 | NR | NR | |
| Individual 4 | 0.21 | 5.59 | |
| Individual 5 | NR | NR | |
| Individual 6 | 0.25 | 6.73 | |
| Individual 7 | 0.24 | 6.39 | |
| Individual 8 | NR | NR | |
| Individual 9 | 0.23 | 6.14 | |
| Individual 10 | 0.21 | 5.69 | |
| Mean NHS (reportable) | 0.23 | 6.12 | |
| AML donor serum (AML) | AML Donor 1 | 0.14 | 3.76 |
| AML Donor 2 | 0.14 | 3.71 | |
| AML Donor 3 | NR | NR | |
| AML Donor 4 | 0.15 | 3.92 | |
| AML Donor 5 | 0.16 | 4.32 | |
| AML Donor 6 | 0.13 | 3.61 | |
| AML Donor 7 | NR | NR | |
| AML Donor 8 | 0.17 | 4.44 | |
| AML Donor 9 | 0.14 | 3.81 | |
| AML Donor 10 | NR | NR | |
| Mean AML (reportable) | 0.15 | 3.94 |
Healthy human and AML patient serum samples (n = 10 per each) were analyzed for sCD33 levels using mass spectroscopy. The concentration of C2-domain sCD33 in these samples was <3 ng/mL (0.11 nM).
NHS, normal human serum; NR, not reportable.